Evidence map›Paper›PMID 27978873›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2016

[Relationship between ID1 and EGFR-TKI Resistance 
in Non-small Cell Lung Cancer].

Yuchen Bao, Yinmin Zhao, Bin Chen, Jie Luo, Qinfang Deng, Hui Sun, Boxiong Xie, Songwen Zhou

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yuchen BaoDepartment of Oncology, Pulmonary Disease Hospital of Tongji University, Shanghai 200433, China.
Yinmin ZhaoDepartment of Oncology, Pulmonary Disease Hospital of Tongji University, Shanghai 200433, China.
Bin ChenDepartment of Oncology, Pulmonary Disease Hospital of Tongji University, Shanghai 200433, China.
Jie LuoDepartment of Oncology, Pulmonary Disease Hospital of Tongji University, Shanghai 200433, China.
Qinfang DengDepartment of Oncology, Pulmonary Disease Hospital of Tongji University, Shanghai 200433, China.
Hui SunDepartment of Thoracic Surgery, Pulmonary Disease Hospital of Tongji University, Shanghai 200433, China.
Boxiong XieDepartment of Thoracic Surgery, Pulmonary Disease Hospital of Tongji University, Shanghai 200433, China.
Songwen ZhouDepartment of Oncology, Pulmonary Disease Hospital of Tongji University, Shanghai 200433, China.
Shanghai Pulmonary Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-small cell lung cancer (NSCLC) presents the highest morbidity and mortality among malignant tumors worldwide. The overall effective rate of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is 30% to 40%, and PFS (progression-free sruvival) is 12 months. However, EGFR-TKI resistance is typical in clinical observations, and this phenomenon significantly affects tumor suppression. To overcome this resistance, a new prognostic factor associated with lung cancer drug resistance should be discovered. This study investigated the relationship between the inhibitor of differentiation 1 (ID1) and non-small cell lung cancer EGFR-TKI resistance in vivo and in vitro to determine any statistical significance and discuss the underlying mechanism.

methodsWestern blot and qRT-PCR were used to quantify the expression of ID1 in lung cancer. IHC was used to detect the expression of ID1 in pathological tissues (lung cancer tissues and adjacent tissues). MTT was used to detect cell proliferation, in which the cells were treated with gefitinib after being transfected by ID1 slow virus vector. Lung cancer cells were inoculated in nude mice until the tumor diameter grew to certain measurement. Gefitinib treatment was started, and the tumor volume was estimated.

resultsID1 was highly expressed in NSCLC (P<0.05). Both ID1 expression and drug resistance of EGFR-TKI in NSCLC were positively correlated (P<0.05). The treatment group with gefitinib showed obviously less expression than the control group.

conclusionsID1 is highly expressed in NSCLC. ID1 expression was positively related to drug resistance of EGFR-TKI in NSCLC. Gefitinib can be used to effectively treat NSCLC, and the mechanism may be associated with an increased level of STAT3 phosphorylation.

Indexed as

Drug Resistance, NeoplasmAnimalsCarcinoma, Non-Small-Cell LungCell Line, TumorErbB ReceptorsHumansInhibitor of Differentiation Protein 1Lung NeoplasmsMiceMice, Inbred BALB CMice, NudeProtein Kinase InhibitorsErbB ReceptorsID1 protein, humanIdb1 protein, mouseInhibitor of Differentiation Protein 1Protein Kinase Inhibitors

Identifiers

PMID27978873
PMCPMC5973454
OpenAlexW2980770048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.